Analyst consensus points to Q2 revenue of $3.00 million and an EPS loss of -$1.69, while the stock currently trades at $34.20, significantly below the average analyst price target of $115.00. Investors are primarily focused on the upcoming Phase 2 clinical data readout for CUE-221 in Chronic Spontaneous Urticaria (CSU), which is anticipated by the end of the third quarter.
The company recently bolstered its financial position with a $50 million private placement and the appointment of a new Chief Medical Officer and Chief Financial Officer. These developments follow a strategic transformation and a 1-for-30 reverse stock split earlier in the year as the company shifts its focus toward its allergic and autoimmune disease pipeline.